Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Fingolimod phosphate promotes the neuroprotective effects of microglia.
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Fingolimod-A sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes.
Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose.
The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community.
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.
RILUTEK®
The INCAT disability score: A critical analysis of its measurement properties.
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial.
Copolymer 1 inhibits manifestations of graft rejection.
The history of the oxazaphosphorine cytostatics.
Pediatric multiple sclerosis.
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome.
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Increased axonal expression of nectin-1 in multiple sclerosis plaques.
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Fingolimod modulates microglial activation to augment markers of remyelination.
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
Pages
« first
‹ previous
…
131
132
133
134
135
136
137
138
139
…
next ›
last »